Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z8PT
|
||||
| Former ID |
DIB019084
|
||||
| Drug Name |
CCT244747
|
||||
| Synonyms |
compound 26 [PMID 23082860]
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H24N8O2
|
||||
| InChI |
InChI=1S/C20H24N8O2/c1-13(11-27(2)3)30-20-16(7-21)22-10-19(26-20)25-18-6-17(29-5)15(9-23-18)14-8-24-28(4)12-14/h6,8-10,12-13H,11H2,1-5H3,(H,23,25,26)/t13-/m1/s1
|
||||
| InChIKey |
IENLGMOXAQMNEH-CYBMUJFWSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | BR serine/threonine kinase 1 | Target Info | Inhibitor | [1] | |
| Serine/threonine-protein kinase Chk1 | Target Info | Inhibitor | [1] | ||
| BR serine/threonine kinase 2 | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Cell cycle | ||||
| p53 signaling pathway | |||||
| HTLV-I infection | |||||
| Viral carcinogenesis | |||||
| Pathway Interaction Database | Fanconi anemia pathway | ||||
| p73 transcription factor network | |||||
| ATR signaling pathway | |||||
| Circadian rhythm pathway | |||||
| p53 pathway | |||||
| Reactome | Activation of ATR in response to replication stress | ||||
| Processing of DNA double-strand break ends | |||||
| Presynaptic phase of homologous DNA pairing and strand exchange | |||||
| G2/M DNA damage checkpoint | |||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |||||
| WikiPathways | DNA Damage Response | ||||
| Signaling by SCF-KIT | |||||
| ATM Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell Cycle | |||||
| Cell Cycle Checkpoints | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| REF 1 | Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.